Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Thomas Kennedy

Neurology Anchorage, AK Medical Doctor

NPI 1225058951 CMS profile 426569

3841 Piper St, Ste T345, Anchorage, AK 99508

Open in the dashboard

General payments

$1,020

24 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Thomas Kennedy of Anchorage, AK is reported in the CMS Open Payments database as having received $1,020 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $29 1
2019 General $991 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Kennedy
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Thomas Kennedy were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Thomas Kennedy Neurology median Middle half National median
2019 $991 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $29 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Teva Pharmaceuticals USA, Inc. $263 5 payments
  2. EMD Serono, Inc. $240 4 payments
  3. Neurocrine Biosciences, Inc. $172 2 payments
  4. LivaNova USA, Inc. $94 1 payment
  5. Novartis Pharmaceuticals Corporation $53 1 payment
  6. Sunovion Pharmaceuticals Inc. $41 2 payments
  7. Ge Healthcare $35 2 payments
  8. AbbVie, Inc. $29 1 payment
  9. Allergan Inc. $23 1 payment
  10. Jazz Pharmaceuticals Inc. $18 1 payment
  11. Other $52 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $1,020 24 payments
Products named General payments · program years 2019–2021
  1. AUSTEDO $246 4 payments
  2. INGREZZA $172 2 payments
  3. Mavenclad $138 3 payments
  4. Rebif $102 1 payment
  5. VNS Therapy $94 1 payment
  6. APTIOM $41 2 payments
  7. UBRELVY $29 1 payment
  8. VRAYLAR $23 1 payment
  9. XYREM $18 1 payment
  10. Ajovy $17 1 payment
  11. Other $52 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record